Pharmacoeconomic review report Edoxaban (Lixiana)
Edoxaban (Lixiana) is indicated for the treatment of venous thromboembolism (VTE) and the prevention of recurrent VTE.1 The dose is 60 mg once daily. The cost per day of treatment with edoxaban is 2 .84. The manufacturer submitted a cost-utility analysis conducted using a simple Markov model with ei...
| Autor principal: | |
|---|---|
| Autor Corporativo: | |
| Formato: | Libro electrónico |
| Idioma: | Inglés |
| Publicado: |
Ottawa (ON) :
Canadian Agency for Drugs and Technologies in Health
2017.
|
| Materias: | |
| Ver en Biblioteca Universitat Ramon Llull: | https://discovery.url.edu/permalink/34CSUC_URL/1im36ta/alma991009820270206719 |
